References
- Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012; 21:418-29; PMID:22439937; http://dx.doi.org/10.1016/j.ccr.2012.01.007
- Martinez-Bosch N, Martinez-Bosch MG, Moreno M, Ortiz-Zapater E, Munne-Collado J, Iglesias M, André S, Gabius HJ, Hwang RF, Poirier F, et al. Galectin-1 Drives pancreatic carcinogenesis through stroma remodeling and hedgehog signaling activation. Cancer Res 2014; 74:3512-24.
- Roda O, Ortiz-Zapater E, Martinez-Bosch N, Gutierrez-Gallego R, Vila-Perello M, Ampurdanes C, Gabius HJ, Andre S, Andreu D, Real FX, et al. Galectin-1 is a novel functional receptor for tissue plasminogen activator in pancreatic cancer. Gastroenterology 2009;136:1379-5; PMID:19171142; http://dx.doi.org/10.1053/j.gastro.2008.12.039
- Chen R, Pan S, Ottenhof NA, de Wilde RF, Wolfgang CL, Lane Z, Post J, Bronner MP, Willmann JK, Maitra A, et al. Stromal galectin-1 expression is associated with long-term survival in resectable pancreatic ductal adenocarcinoma. Cancer Biol Ther 2012; 13:899-907; PMID:22785208; http://dx.doi.org/10.4161/cbt.20842
- Ito K, Stannard K, Gabutero E, Clark AM, Neo SY, Onturk S, Blanchard H, Ralph SJ. Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment. Cancer Metastasis Rev 2012; 31:763-8; PMID:22706847; http://dx.doi.org/10.1007/s10555-012-9388-2
- Tang D, Yuan Z, Xue X, Lu Z, Zhang Y, Wang H, Chen M, An Y, Wei J, Zhu Y, et al. High expression of Galectin-1 in pancreatic stellate cells plays a role in the development and maintenance of an immunosuppressive microenvironment in pancreatic cancer. Int J Cancer 2012; 130:2337-48; PMID:21780106; http://dx.doi.org/10.1002/ijc.26290
- La M, Cao TV, Cerchiaro G, Chilton K, Hirabayashi J, Kasai K, Oliani SM, Chernajovsky Y, Perretti M. A novel biological activity for galectin-1: inhibition of leukocyte-endothelial cell interactions in experimental inflammation. Am J Pathol 2003; 163:1505-15; PMID:14507657; http://dx.doi.org/10.1016/S0002-9440(10)63507-9
- Sideras K, Braat H, Kwekkeboom J, van Eijck CH, Peppelenbosch MP, Sleijfer S, Bruno M. Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies. Cancer Treat Rev 2014; 40:513-22; PMID:24315741; http://dx.doi.org/10.1016/j.ctrv.2013.11.005
- Wormann SM, Diakopoulos KN, Lesina M, Algul H. The immune network in pancreatic cancer development and progression. Oncogene 2014; 33:2956-67.
- Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, Serova M, Neuzillet C, Albert S, Raymond E, Faivre S. Unraveling galectin-1 as a novel therapeutic target for cancer. Cancer Treat Rev 2014; 40:307-19; PMID:23953240; http://dx.doi.org/10.1016/j.ctrv.2013.07.007